ES2685503T3 - Métodos de medida de la división in vivo de Factor von Willebrand mediada por ADAMTS13 y utilización de los mismos - Google Patents
Métodos de medida de la división in vivo de Factor von Willebrand mediada por ADAMTS13 y utilización de los mismos Download PDFInfo
- Publication number
- ES2685503T3 ES2685503T3 ES09764426T ES09764426T ES2685503T3 ES 2685503 T3 ES2685503 T3 ES 2685503T3 ES 09764426 T ES09764426 T ES 09764426T ES 09764426 T ES09764426 T ES 09764426T ES 2685503 T3 ES2685503 T3 ES 2685503T3
- Authority
- ES
- Spain
- Prior art keywords
- vwf
- adamts13
- von willebrand
- cleavage fragments
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
- G01N2333/755—Factors VIII, e.g. factor VIII C [AHF], factor VIII Ag [VWF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96486—Metalloendopeptidases (3.4.24)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
- G01N2800/224—Haemostasis or coagulation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Método para analizar la eficacia de un factor de von Willebrand (FvW) utilizado en el tratamiento de la enfermedad de von Willebrand (EvW) en un individuo, que comprende medir fragmentos de división de FvW en una muestra de sangre del individuo antes y después del tratamiento, en el que un aumento de los fragmentos de división de FvW después del tratamiento indica que una desintegrina y metaloproteinasa con un motivo de trombospondina de tipo 1, miembro 13 (ADAMTS13) endógena en el individuo está dividiendo el FvW, y en el que una disminución o una ausencia de fragmentos de división de FvW después del tratamiento indica que la ADAMTS13 endógena en el sujeto no está dividiendo el FvW, y en el que los fragmentos de división de FvW son generados por la actividad de la ADAMTS13, y en el que la división de FvW se lleva a cabo bajo tensión de cizalladura.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12020208P | 2008-12-05 | 2008-12-05 | |
PCT/US2009/066588 WO2010065742A1 (en) | 2008-12-05 | 2009-12-03 | Methods of measuring adamts13-mediated in vivo cleavage of von willebrand factor and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2685503T3 true ES2685503T3 (es) | 2018-10-09 |
Family
ID=41682841
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES09764426T Active ES2685503T3 (es) | 2008-12-05 | 2009-12-03 | Métodos de medida de la división in vivo de Factor von Willebrand mediada por ADAMTS13 y utilización de los mismos |
Country Status (9)
Country | Link |
---|---|
US (6) | US8415114B2 (es) |
EP (2) | EP2358895B1 (es) |
JP (4) | JP6111016B2 (es) |
KR (1) | KR101670103B1 (es) |
AU (1) | AU2009322367B2 (es) |
CA (2) | CA3098952A1 (es) |
ES (1) | ES2685503T3 (es) |
PL (1) | PL2358895T3 (es) |
WO (1) | WO2010065742A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2009322367B2 (en) * | 2008-12-05 | 2015-03-26 | Takeda Pharmaceutical Company Limited | Methods of measuring ADAMTS13-mediated in vivo cleavage of von Willebrand factor and uses thereof |
CA2757585C (en) * | 2010-11-17 | 2022-07-19 | Puget Sound Blood Center | Enhanced cleavage of von willebrand factor by adamts13 |
KR102386584B1 (ko) | 2016-10-11 | 2022-04-14 | 래버러토리 코포레이션 오브 아메리카 홀딩스 | Adamts13 효소 활성을 결정하기 위한 방법 및 시스템 |
JP7120558B2 (ja) * | 2017-09-27 | 2022-08-17 | 国立大学法人東北大学 | せん断応力負荷時のフォンウィルブランド因子高分子マルチマーの保持率のインビトロ測定法 |
JP7359775B2 (ja) * | 2018-09-14 | 2023-10-11 | テルモ株式会社 | 循環器障害または血栓形成の進行またはそのリスクの予測 |
WO2020160460A1 (en) * | 2019-02-01 | 2020-08-06 | Baxalta Incorporated | Methods of prophylactic treatment using recombinant vwf (rvwf) |
WO2020247746A1 (en) * | 2019-06-07 | 2020-12-10 | Baxalta Incorporated | Use of recombinant adamts13 for treating sickle cell disease |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003284570A (ja) * | 2001-04-25 | 2003-10-07 | Chemo Sero Therapeut Res Inst | フォンビルブラント因子(vWF)切断酵素 |
AU2002336367A1 (en) * | 2001-08-16 | 2003-03-03 | The Regents Of The University Of Michigan | Adamts13 genes and proteins and variants, and uses thereof |
DE20213920U1 (de) * | 2002-07-03 | 2003-01-16 | Boehm Martina | Diagnostikum zum Nachweis der den von Willebrand-Faktorspaltenden Aktivität von ADAMTS13 |
WO2004029242A1 (ja) * | 2002-09-25 | 2004-04-08 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | フォンビルブランド因子特異的切断酵素に対する抗体及びそれを用いたアッセイ系 |
US7718763B2 (en) * | 2002-10-18 | 2010-05-18 | Japan As Represented By The President Of National Cardiovascular Center | Substrate polyeptides for von Willebrand factor cleaving protease ADAMTS-13 |
EP1642128B1 (en) | 2003-07-07 | 2016-11-16 | University Of North Carolina At Chapel Hill | Method and system for detection of von willebrand factor (vwf) multimers |
US7270976B2 (en) * | 2004-07-19 | 2007-09-18 | American Diagnostica, Inc. | Methods for measuring ADAMTS13 activity and protein on platelets and in plasma |
JP4913034B2 (ja) * | 2005-02-14 | 2012-04-11 | アルフレッサファーマ株式会社 | Adamts13活性検定用抗体及び活性検定方法 |
ATE544866T1 (de) * | 2005-06-17 | 2012-02-15 | Baxter Int | Adamts13-haltige zusammensetzungen mit thrombolytischer wirkung |
JP2007024839A (ja) | 2005-07-21 | 2007-02-01 | Sekisui Chem Co Ltd | 検体採取容器 |
WO2007088849A1 (ja) | 2006-01-31 | 2007-08-09 | Mitsubishi Kagaku Iatron, Inc. | 播種性血管内凝固症候群の病態把握方法 |
JP4820192B2 (ja) * | 2006-03-17 | 2011-11-24 | 一般財団法人化学及血清療法研究所 | 急性冠症候群でのadamts13の測定と利用 |
AU2008259839A1 (en) * | 2007-05-31 | 2008-12-11 | The Children's Hospital Of Philadelphia | Compositions and methods for modulation of ADAMTS13 activity |
ES2713270T3 (es) * | 2008-10-27 | 2019-05-20 | Baxalta GmbH | Modelos de ratón de púrpura trombocitopénica trombótica y métodos para su uso |
AU2009322367B2 (en) * | 2008-12-05 | 2015-03-26 | Takeda Pharmaceutical Company Limited | Methods of measuring ADAMTS13-mediated in vivo cleavage of von Willebrand factor and uses thereof |
EP4218797A1 (en) * | 2009-09-21 | 2023-08-02 | Takeda Pharmaceutical Company Limited | Stabilized liquid and lyophilized adamts13 formulations |
WO2012006594A1 (en) * | 2010-07-08 | 2012-01-12 | Baxter International Inc. | Method of producing recombinant adamts13 in cell culture |
CA2757585C (en) * | 2010-11-17 | 2022-07-19 | Puget Sound Blood Center | Enhanced cleavage of von willebrand factor by adamts13 |
-
2009
- 2009-12-03 AU AU2009322367A patent/AU2009322367B2/en active Active
- 2009-12-03 EP EP09764426.4A patent/EP2358895B1/en active Active
- 2009-12-03 PL PL09764426T patent/PL2358895T3/pl unknown
- 2009-12-03 JP JP2011539696A patent/JP6111016B2/ja active Active
- 2009-12-03 US US12/630,509 patent/US8415114B2/en active Active
- 2009-12-03 EP EP18173838.6A patent/EP3388529A1/en active Pending
- 2009-12-03 WO PCT/US2009/066588 patent/WO2010065742A1/en active Application Filing
- 2009-12-03 CA CA3098952A patent/CA3098952A1/en not_active Abandoned
- 2009-12-03 CA CA2745805A patent/CA2745805C/en active Active
- 2009-12-03 KR KR1020117015378A patent/KR101670103B1/ko active IP Right Grant
- 2009-12-03 ES ES09764426T patent/ES2685503T3/es active Active
-
2013
- 2013-03-12 US US13/795,214 patent/US8623612B2/en active Active
- 2013-11-12 US US14/078,324 patent/US9110085B2/en active Active
-
2014
- 2014-11-20 US US14/549,404 patent/US9488651B2/en active Active
-
2015
- 2015-07-03 JP JP2015134417A patent/JP2015213513A/ja not_active Withdrawn
-
2016
- 2016-11-07 US US15/345,070 patent/US10209263B2/en active Active
-
2017
- 2017-06-14 JP JP2017116794A patent/JP6691893B2/ja active Active
-
2019
- 2019-01-16 US US16/248,868 patent/US10900979B2/en active Active
- 2019-11-21 JP JP2019210455A patent/JP2020022515A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3098952A1 (en) | 2010-06-10 |
US8623612B2 (en) | 2014-01-07 |
CA2745805A1 (en) | 2010-06-10 |
US20100143957A1 (en) | 2010-06-10 |
JP6691893B2 (ja) | 2020-05-13 |
WO2010065742A1 (en) | 2010-06-10 |
CA2745805C (en) | 2021-01-19 |
US10900979B2 (en) | 2021-01-26 |
AU2009322367A1 (en) | 2011-06-30 |
US10209263B2 (en) | 2019-02-19 |
PL2358895T3 (pl) | 2019-03-29 |
JP6111016B2 (ja) | 2017-04-05 |
EP2358895B1 (en) | 2018-05-30 |
US9488651B2 (en) | 2016-11-08 |
US8415114B2 (en) | 2013-04-09 |
EP2358895A1 (en) | 2011-08-24 |
JP2012510817A (ja) | 2012-05-17 |
JP2017153490A (ja) | 2017-09-07 |
US20140154709A1 (en) | 2014-06-05 |
US9110085B2 (en) | 2015-08-18 |
EP3388529A1 (en) | 2018-10-17 |
US20130252263A1 (en) | 2013-09-26 |
KR20110104940A (ko) | 2011-09-23 |
JP2020022515A (ja) | 2020-02-13 |
US20190145989A1 (en) | 2019-05-16 |
AU2009322367B2 (en) | 2015-03-26 |
KR101670103B1 (ko) | 2016-10-27 |
US20160033506A1 (en) | 2016-02-04 |
JP2015213513A (ja) | 2015-12-03 |
US20170153255A1 (en) | 2017-06-01 |
EP3388529A8 (en) | 2018-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2685503T3 (es) | Métodos de medida de la división in vivo de Factor von Willebrand mediada por ADAMTS13 y utilización de los mismos | |
BR112015022216A2 (pt) | método e dispositivo para correção de sinais ópticos | |
AR058550A1 (es) | Analisis in vivo no invasivo, por impedancia bioelectrica de cambios en tejidos mediados por glucosa | |
UY31170A1 (es) | Compuestos moduladores de sirtuina | |
AR095363A1 (es) | Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1 | |
CL2017000546A1 (es) | Análisis de coagulación universal microfluídico basado en chips | |
CR20120326A (es) | Dispositivo portátil de monitorización de la coagulación y método de evaluación de la respuesta de coagulación | |
ES2618506T3 (es) | Marcador epigenético para la identificación de linfocitos T CD3CD4 positivos | |
MD3529262T2 (ro) | Metode pentru promovarea răspunsului celulelor T | |
Draenert et al. | The prevalence of tooth hypersensitivity following periodontal therapy with special reference to root scaling. A systematic review of the literature. | |
Moretti et al. | The influence of restorations and prosthetic crowns finishing lines on inflammatory levels after non-surgical periodontal therapy. | |
CL2008003282A1 (es) | Poblacion de celulas humanas que expresan cd34 las cuales son obtenidas a partir de expansion de celulas de sangre de cordon umbilical en presencia de celulas menstruales humanas, metodo para obtener dichas celulas. | |
Boteon et al. | Effect of different concentrations and application times of proanthocyanidin gels on dentin erosion. | |
PH12014501445B1 (en) | Detection of human umbilical cord tissue-derived cells | |
BR112015021507A2 (pt) | métodos e composições para o diagnóstico de pré-eclampsia | |
ES2671248T3 (es) | Métodos para tratar el cáncer que comprenden un guiado por NQO1 | |
AR109279A1 (es) | Anticuerpos anti plazomicina y métodos de uso de los mismos | |
Mancinelli et al. | Age-associated declining of the regeneration potential of skeletal stem/progenitor cells | |
Cesar et al. | Analyses by photoreflectance spectroscopy and Vickers hardness of conventional and laser-assisted tooth bleaching. | |
Tandon et al. | Label-free multiphoton microscopy for the detection and monitoring of calcific aortic valve disease | |
AR064682A1 (es) | Metodo para medir la concentracion del factor (vii a) en una muestra | |
CO2017003215A1 (es) | Biosensor para la medicion biofisica de la secrecion cervical | |
CL2019003161A1 (es) | Métodos de tratamiento selectivo del asma usando antagonistas de il-17. | |
AR097591A1 (es) | Métodos para determinar la respuesta a la terapia | |
AR112674A1 (es) | Métodos de tratamiento de cáncer con inhibidores de farnesiltransferasa |